Zai Lab Limited (ZLAB) IPO Prices at $18

Zai Lab Limited (NASDAQ: ZLAB) announces the pricing of its U.S. initial public offering of American depositary shares, raising gross proceeds of approximately US$150.0 million.

8,333,333 ADSs were sold in the IPO at a price of US$18.00 per ADS. Each ADS represents one ordinary share of Zai Lab. The ADSs have been approved for listing on the Nasdaq Global Market and are expected to begin trading on September 20, 2017 under the ticker symbol “ZLAB.”

In addition, Zai Lab has granted the underwriters a 30-day option to purchase up to an additional 1,250,000 ADSs at the IPO price. Closing of the IPO is expected to occur on or about September 22, 2017, subject to customary closing conditions.

J.P. Morgan, Citigroup and Leerink Partners are acting as joint book-running managers for the IPO.

Zai LabZai Lab (NASDAQ: ZLAB) is a Shanghai-based innovative biopharmaceutical company focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world. The company’s experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates targeting the fast growing segments of China’s pharmaceutical market and global unmet medical needs. Zai Lab’s vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its partner’s and its own products in order to impact human health worldwide.

You May Also Be Interested In

• SpaceX prices historic IPO at $135/share in largest ever new listing
• SpaceX prices IPO at $135 per share for June 12 Nasdaq debut
• D. Boral Capital Acted as Co-Lead Underwriter to Aeon Acquisition I Corp. (NASDAQ:AESPU) in Connection with its $143,750,000 Initial Public Offering and Full Exercise of Underwriters’ Option to Pur